Substance-related Disorders Clinical Trial
Official title:
Group Motivational Interviewing (GMI) For Homeless Veterans In VA Services
Verified date | July 2023 |
Source | VA Office of Research and Development |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Homeless Veterans with substance use disorders (SUDs) are a major group served by VA and are heavily represented in VA housing. VA recently adopted a 'Housing First' approach emphasizing rapid housing placement to initiate recovery without requiring sobriety and will necessitate SUD interventions that are efficient and easily layered onto existing services. The proposed study will investigate the effectiveness, implementation process, and cost estimate of Group Motivational Interviewing (GMI) for Veterans with SUDs in VA housing (Housing Urban Development-VA Support Housing [HUD-VASH] and Grant and per Diem [GPD]). Outcomes will be assessed at multiple time points using a multi-modal approach. The ultimate goal of this research is to establish the basis of a GMI dissemination and implementation course of action for highly vulnerable homeless Veterans in VA housing for achieving their greatest success in attaining housing stability.
Status | Completed |
Enrollment | 185 |
Est. completion date | July 17, 2018 |
Est. primary completion date | July 17, 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 75 Years |
Eligibility | Inclusion Criteria: - Men and women Veterans currently in Housing Urban Development-VA Support Housing [HUD-VASH] and Grant and per Diem [GPD]), newly entering the program but not yet housed, or Veterans on the HUD-VASH interest (wait) list. - Able to comprehend English. - Meets DSM-V criteria for a current substance use disorder and have used substances in the 30 days prior to treatment entry. Participants on medications targeting their substance use must be stabilized on medications for at least 2 weeks before therapy initiation. - May meet criteria a mood, anxiety or other psychiatric disorder. Participants on maintenance medications for a mood or anxiety disorder must be stabilized on medications for at least 2 weeks before therapy initiation. - Able to adequately provide informed consent and function at an intellectual level sufficient to allow accurate completion of all assessment instruments. - Willing to commit to 4 group therapy sessions, baseline, 1, 3, and 6 month follow-up assessments. Exclusion Criteria: - Active suicidal or homicidal ideation with a plan as this is likely to require hospitalization or other interventions that could interfere with study participation. - Unstable psychiatric condition that is likely to require hospitalization or other interventions that would interfere with study participation. - Unstable medical condition or one that may require hospitalization during the course of the study. |
Country | Name | City | State |
---|---|---|---|
United States | Ralph H. Johnson VA Medical Center, Charleston, SC | Charleston | South Carolina |
Lead Sponsor | Collaborator |
---|---|
VA Office of Research and Development |
United States,
Gebregziabher M, Voronca D, Teklehaimanot A, Santa Ana EJ. Weibull mixture regression for marginal inference in zero-heavy continuous outcomes. Stat Methods Med Res. 2017 Jun;26(3):1476-1499. doi: 10.1177/0962280215583402. Epub 2015 Apr 22. — View Citation
Jaconis M, Santa Ana EJ, Killeen TK, Badour CL, Back SE. Concurrent treatment of PTSD and alcohol use disorder via telehealth in a female Iraq veteran. Am J Addict. 2017 Mar;26(2):112-114. doi: 10.1111/ajad.12481. Epub 2017 Jan 24. — View Citation
Santa Ana EJ, LaRowe SD, Armeson K, Lamb KE, Hartwell K. Impact of group motivational interviewing on enhancing treatment engagement for homeless Veterans with nicotine dependence and other substance use disorders: A pilot investigation. Am J Addict. 2016 — View Citation
Shorey RC, Martino S, Lamb KE, LaRowe SD, Santa Ana EJ. Change talk and relatedness in group motivational interviewing: a pilot study. J Subst Abuse Treat. 2015 Apr;51:75-81. doi: 10.1016/j.jsat.2014.11.003. Epub 2014 Nov 20. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Standard Ethanol Content Units (SECs) Baseline | The Timeline Follow-Back (TLFB) calendar was used to assess retrospective self-report of alcohol in the 30 days prior to baseline. Amount of alcohol consumption was converted to standard ethanol content units (SECs; or standard drinks) equivalent to 0.5 oz. of ethanol. This measure represents ALL standard drinks consumed within the stated time period. | 30 days prior to Baseline | |
Primary | Standard Ethanol Content Units (SECs) at 1 Month | The 1-month follow-up was conducted 30 days after day 1 of the treatment group. The Timeline Follow-Back (TLFB) calendar was used to assess retrospective self-report of alcohol in the 30 days prior to 1-month follow-up. Amount of alcohol consumption was converted to standard ethanol content units (SECs; or standard drinks) equivalent to 0.5 oz. of ethanol. This measure represents ALL standard drinks consumed within the stated time period. | 1 month | |
Primary | Standard Ethanol Content Units (SECs) at 3 Months | The 3-month follow-up was conducted 60 days after the 1-month follow-up. The Timeline Follow-Back (TLFB) calendar was used to assess retrospective self-report of alcohol in the 60 days prior to 3-month follow-up. Amount of alcohol consumption was converted to standard ethanol content units (SECs; or standard drinks) equivalent to 0.5 oz. of ethanol. This measure represents ALL standard drinks consumed within the stated time period. | 3 months | |
Primary | Standard Ethanol Content Units (SECs) at 6 Months | The 6-month follow-up was conducted 90 days after the 3-month follow-up. The Timeline Follow-Back (TLFB) calendar was used to assess retrospective self-report of alcohol in the 90 days prior to 6-month follow-up. Amount of alcohol consumption was converted to standard ethanol content units (SECs; or standard drinks) equivalent to 0.5 oz. of ethanol. This measure represents ALL standard drinks consumed within the stated time period. | 6 months | |
Primary | Peak SEC at Baseline | The Timeline Follow-Back (TLFB) calendar was used to assess retrospective self-report of alcohol in the 30 days prior to baseline. Amount of alcohol consumption was converted to standard ethanol content units (SECs; or standard drinks) equivalent to 0.5 oz. of ethanol. This measure represents the most standard drinks consumed in a single day within the stated time period. | 30 days prior to Baseline | |
Primary | Peak SEC at 1 Month | The 1-month follow-up was conducted 30 days after day 1 of the treatment group. The Timeline Follow-Back (TLFB) calendar was used to assess retrospective self-report of alcohol in the 30 days prior to 1-month follow-up. Amount of alcohol consumption was converted to standard ethanol content units (SECs; or standard drinks) equivalent to 0.5 oz. of ethanol. This measure represents the most standard drinks consumed on a single day within the stated time period. | 1 month | |
Primary | Peak SEC at 3 Months | The 3-month follow-up was conducted 60 days after the 1-month follow-up. The Timeline Follow-Back (TLFB) calendar was used to assess retrospective self-report of alcohol in the 60 days prior to 3-month follow-up. Amount of alcohol consumption was converted to standard ethanol content units (SECs; or standard drinks) equivalent to 0.5 oz. of ethanol. This measure represents the most standard drinks consumed on a single day within the stated time period. | 3 months | |
Primary | Peak SEC at 6 Months | The 6-month follow-up was conducted 90 days after the 3-month follow-up. The Timeline Follow-Back (TLFB) calendar was used to assess retrospective self-report of alcohol in the 90 days prior to 6-month follow-up. Amount of alcohol consumption was converted to standard ethanol content units (SECs; or standard drinks) equivalent to 0.5 oz. of ethanol. This measure represents the most standard drinks consumed on a single day within the stated time period. | 6 months | |
Primary | Alcohol Drink Days at Baseline | The Timeline Follow-Back (TLFB) calendar was used to assess retrospective self-report of alcohol in the 30 days prior to Baseline. This measure represents the number of days any alcohol was consumed within the stated time period. | 30 days prior to Baseline | |
Primary | Alcohol Drink Days at 1 Month | The Timeline Follow-Back (TLFB) calendar was used to assess retrospective self-report of alcohol in the 30 days after day 1 of the treatment group. This measure represents the number of days any alcohol was consumed within the stated time period. | 1 month | |
Primary | Alcohol Drink Days at 3 Months | The Timeline Follow-Back (TLFB) calendar was used to assess retrospective self-report of alcohol in the 60 days prior to 3-month follow-up. This measure represents the number of days any alcohol was consumed within the stated time period. | 3 months | |
Primary | Alcohol Drink Days at 6 Months | The Timeline Follow-Back (TLFB) calendar was used to assess retrospective self-report of alcohol in the 90 days prior to 6-month follow-up. This measure represents the number of days any alcohol was consumed within the stated time period. | 6 months | |
Primary | Binge Drink Days at Baseline | The Timeline Follow-Back (TLFB) calendar was used to assess retrospective self-report of alcohol in the 30 days prior to Baseline. This measure represents the number of days the participant binge drank (5 or more standard drinks on a single day for males; 4 or more standard drinks on a single day for females). | 30 days prior to Baseline | |
Primary | Binge Drink Days at 1 Month | The Timeline Follow-Back (TLFB) calendar was used to assess retrospective self-report of alcohol in the 30 days prior to 1-month follow-up. This measure represents the number of days the participant binge drank (5 or more standard drinks on a single day for males; 4 or more standard drinks on a single day for females) within the stated time period. | 1 month | |
Primary | Binge Drink Days at 3 Months | The Timeline Follow-Back (TLFB) calendar was used to assess retrospective self-report of alcohol in the 60 days prior to 3-month follow-up. This measure represents the number of days the participant binge drank (5 or more standard drinks on a single day for males; 4 or more standard drinks on a single day for females) within the stated time period. | 3 months | |
Primary | Binge Drink Days at 6 Months | The Timeline Follow-Back (TLFB) calendar was used to assess retrospective self-report of alcohol in the 90 days prior to 6-month follow-up. This measure represents the number of days the participant binge drank (5 or more standard drinks on a single day for males; 4 or more standard drinks on a single day for females) within the stated time period. | 6 months | |
Primary | Illicit Drug Use Days at Baseline | The Timeline Follow-Back (TLFB) calendar was used to assess retrospective self-report of drug use in the 30 days prior to Baseline. This measure represents the number of illicit drug use days within the stated time period. | 30 days prior to Baseline | |
Primary | Illicit Drug Use Days at 1 Month | The Timeline Follow-Back (TLFB) calendar was used to assess retrospective self-report of alcohol in the 30 days prior to 1-month follow-up. This measure represents the number of illicit drug use days within the stated time period. | 1 month | |
Primary | Illicit Drug Use Days at 3 Months | The Timeline Follow-Back (TLFB) calendar was used to assess retrospective self-report of alcohol in the 60 days prior to 3-month follow-up. This measure represents the number of illicit drug use days within the stated time period. | 3 months | |
Primary | Illicit Drug Use Days at 6 Months | The Timeline Follow-Back (TLFB) calendar was used to assess retrospective self-report of alcohol in the 90 days prior to 6-month follow-up. This measure represents the number of illicit drug use days within the stated time period. | 6 months | |
Primary | Substance Use Disorder Treatment Sessions at Baseline | A Treatment Attendance Calendar was used to record the number of objective treatment sessions documented in each participants VA Computerized Patient Record System for the 30 days prior to Baseline. Treatment sessions included the outpatient substance use disorder treatment group sessions and individual sessions. | 30 days prior to Baseline | |
Primary | Substance Use Disorder Treatment Sessions at 1 Month | A Treatment Attendance Calendar was used to record the number of objective treatment sessions documented in each participants VA Computerized Patient Record System for the 30 days prior to 1-month follow-up. Treatment sessions included the outpatient substance use disorder treatment group sessions and individual sessions. | 1 month | |
Primary | Substance Use Disorder Treatment Sessions at 3 Months | A Treatment Attendance Calendar was used to record the number of objective treatment sessions documented in each participants VA Computerized Patient Record System for the 60 days prior to 3-month follow-up. Treatment sessions included the outpatient substance use disorder treatment group sessions and individual sessions. | 3 months | |
Primary | Substance Use Disorder Treatment Sessions at 6 Months | A Treatment Attendance Calendar was used to record the number of objective treatment sessions documented in each participants VA Computerized Patient Record System for the 60 days prior to 6-month follow-up. Treatment sessions included the outpatient substance use disorder treatment group sessions and individual sessions. | 6 months | |
Primary | Twelve-Step Sessions Attended at Baseline | A Treatment Attendance Calendar was used to record the number of self-reported 12-step sessions attended 30 days prior to Baseline. | 30 days prior to Baseline | |
Primary | Twelve-Step Sessions Attended at 1 Month | A Treatment Attendance Calendar was used to record the number of self-reported 12-step sessions attended 30 days prior to 1-month follow-up. | 1 month | |
Primary | Twelve-Step Sessions Attended at 3 Months | A Treatment Attendance Calendar was used to record the number of self-reported 12-step sessions attended 60 days prior to 3-month follow-up. | 3 months | |
Primary | Twelve-Step Sessions Attended at 6 Months | A Treatment Attendance Calendar was used to record the number of self-reported 12-step sessions attended in the 90 days prior to 6-month follow-up. | 6 months | |
Primary | Times Involved in Community Participation Activities at Baseline | A calendar was used to record the number of times a participant participated in an activity in the community (e.g. museum, library, baseball game) in the 30 days prior to Baseline. | 30 days prior to Baseline | |
Primary | Times Involved in Community Participation Activities at 1 Month | A calendar was used to record the number of times a participant participated in an activity in the community (e.g. museum, library, baseball game) in the 30 days prior to 1-month follow-up. | 1 month | |
Primary | Times Involved in Community Participation Activities at 3 Months | A calendar was used to record the number of times a participant participated in an activity in the community (e.g. museum, library, baseball game) in the 60 days prior to 3-month follow-up. | 3 months | |
Primary | Times Involved in Community Participation Activities at 6 Months | A calendar was used to record the number of times a participant participated in an activity in the community (e.g. museum, library, baseball game) in the 90 days prior to 6-month follow-up. | 6 months | |
Primary | Days Involved in Productive Work Activities at Baseline | A calendar was used to record the number of times a participant participated in a productive work activity (e.g. volunteered or worked at a job) in the 30 days prior to Baseline. | 30 days prior to Baseline | |
Primary | Days Involved in Productive Work Activities at 1 Month | A calendar was used to record the number of times a participant participated in a productive work activity (e.g. volunteered or worked at a job) in the 30 days prior to 1-month follow-up. | 1 month | |
Primary | Days Involved in Productive Work Activities at 3 Months | A calendar was used to record the number of times a participant participated in a productive work activity (e.g. volunteered or worked at a job) in the 60 days prior to 3-month follow-up | 3 months | |
Primary | Days Involved in Productive Work Activities at 6 Months | A calendar was used to record the number of times a participant participated in a productive work activity (e.g. volunteered or worked at a job) in the 90 days prior to 6-month follow-up. | 6 months | |
Secondary | Mental Health Treatment Sessions at Baseline | A Treatment Attendance Calendar was used to record the number of objective treatment sessions documented in each participants VA Computerized Patient Record System for the 30 days prior to Baseline. Treatment sessions included individual sessions with outpatient mental health staff. | 30 days prior to Baseline | |
Secondary | Mental Health Treatment Sessions at 1 Month | A Treatment Attendance Calendar was used to record the number of objective treatment sessions documented in each participants VA Computerized Patient Record System for the 30 days prior to 1-month follow-up. Treatment sessions included individual sessions with outpatient mental health staff. | 1 Month | |
Secondary | Mental Health Treatment Sessions at 3 Months | A Treatment Attendance Calendar was used to record the number of objective treatment sessions documented in each participants VA Computerized Patient Record System for the 60 days prior to 3-month follow-up. Treatment sessions included individual sessions with outpatient mental health staff. | 3 Months | |
Secondary | Mental Health Treatment Sessions at 6 Months | A Treatment Attendance Calendar was used to record the number of objective treatment sessions documented in each participants VA Computerized Patient Record System for the 90 days prior to 6-month follow-up. Treatment sessions included individual sessions with outpatient mental health staff. | 6 Months | |
Secondary | Substance Use Disorder and Mental Health Treatment Sessions at Baseline | This specific measure combined the number substance use disorder treatment sessions and mental health treatment sessions attended for the 30 days prior to Baseline. | 30 days prior to Baseline | |
Secondary | Substance Use Disorder and Mental Health Treatment Sessions at 1 Month | This specific measure combined the number substance use disorder treatment sessions and mental health treatment sessions attended for the 30 days prior to 1-month follow-up. | 1 Month | |
Secondary | Substance Use Disorder and Mental Health Treatment Sessions at 3 Months | This specific measure combined the number substance use disorder treatment sessions and mental health treatment sessions attended for the 60 days prior to 3-month follow-up. | 3 Months | |
Secondary | Substance Use Disorder and Mental Health Treatment Sessions at 6 Months | This specific measure combined the number substance use disorder treatment sessions and mental health treatment sessions attended for the 90 days prior to 6-month follow-up. | 6 Months | |
Secondary | Addiction Severity Index-Lite (ASI-Lite) at Baseline for Alcohol Use | The ASI-Lite will be used to measure addiction severity Min value:0 Max value: 1 Higher score indicates greater problem severity | 30 days prior to Baseline | |
Secondary | Addiction Severity Index-Lite (ASI-Lite) at 1 Month for Alcohol Use | The ASI-Lite will be used to measure addiction severity Min value:0 Max value: 1 Higher score indicates greater problem severity | 1 month | |
Secondary | Addiction Severity Index-Lite (ASI-Lite) at 3 Months for Alcohol Use | The ASI-Lite will be used to measure addiction severity Min value:0 Max value: 1 Higher score indicates greater problem severity | 3 months | |
Secondary | Addiction Severity Index-Lite (ASI-Lite) at 6 Months for Alcohol Use | The ASI-Lite will be used to measure addiction severity Min value:0 Max value: 1 Higher score indicates greater problem severity | 6 months | |
Secondary | Addiction Severity Index-Lite (ASI-Lite) at Baseline for Psychiatric Status | The ASI-Lite will be used to measure addiction severity Min value:0 Max value: 1 Higher score indicates greater problem severity | 30 days prior to Baseline | |
Secondary | Addiction Severity Index-Lite (ASI-Lite) at 1 Month for Psychiatric Status | The ASI-Lite will be used to measure addiction severity Min value:0 Max value: 1 Higher score indicates greater problem severity | 30 days | |
Secondary | Addiction Severity Index-Lite (ASI-Lite) at 3 Month for Psychiatric Status | The ASI-Lite will be used to measure addiction severity Min value:0 Max value: 1 Higher score indicates greater problem severity | 3 months | |
Secondary | Addiction Severity Index-Lite (ASI-Lite) at 6 Months for Psychiatric Status | The ASI-Lite will be used to measure addiction severity Min value:0 Max value: 1 Higher score indicates greater problem severity | 6 months | |
Secondary | Short Inventory of Problems (SIP) at Baseline | Min value:0 Max value: 45 Higher score indicates higher number of consequences from alcohol and drug use | 30 days prior to Baseline | |
Secondary | Short Inventory of Problems at 1 Month | Min value:0 Max value: 45 Higher score indicates higher number of consequences from alcohol and drug use | 1 month | |
Secondary | Short Inventory of Problems at 3 Months | Min value:0 Max value: 45 Higher score indicates higher number of consequences from alcohol and drug use | 3 months | |
Secondary | Short Inventory of Problems at 6 Months | Min value:0 Max value: 45 Higher score indicates higher number of consequences from alcohol and drug use | 6 months | |
Secondary | Social Support Survey Total Score at Baseline | Min value:19 Max value:95 Higher score indicates higher support | 30 days prior to Baseline | |
Secondary | Social Support Survey Total Score at 1 Month | Min value:19 Max value:95 Higher score indicates higher support | 30 days prior to 1-month follow-up | |
Secondary | Social Support Survey Total Score at 3 Months | Min value:19 Max value:95 Higher score indicates higher support | 60 days prior to 3-month follow-up | |
Secondary | Social Support Survey Total Score at 6 Months | Min value:19 Max value:95 Higher score indicates higher support | 90 days prior to 6-month follow-up | |
Secondary | Quality of Life Survey (QOLS) at Baseline | Min value:16 Max value:112 Higher score indicates higher quality of life | 30 days prior to Baseline | |
Secondary | Quality of Life Survey (QOLS) at 1 Month | Min value:16 Max value:112 Higher score indicates higher quality of life | 1 month | |
Secondary | Quality of Life Survey (QOLS) at 3 Months | Min value:16 Max value:112 Higher score indicates higher quality of life | 3 months | |
Secondary | Quality of Life Survey (QOLS) at 6 Months | Min value:16 Max value:112 Higher score indicates higher quality of life | 6 months | |
Secondary | Brief Symptom Inventory (BSI-18) at Baseline | Min value:0 Max value:72 Higher score indicates higher psychological distress | 30 days prior to Baseline | |
Secondary | Brief Symptom Inventory(BSI-18) at 1 Month | Min value:0 Max value:72 Higher score indicates higher psychological distress | 1 month | |
Secondary | Brief Symptom Inventory (BSI-18) at 3 Months | Min value:0 Max value:72 Higher score indicates higher psychological distress | 3 months | |
Secondary | Brief Symptom Inventory (BSI-18) at 6 Months | Min value:0 Max value:72 Higher score indicates higher psychological distress | 6 months | |
Secondary | SF-12 Health Survey Physical Summary Score at Baseline | Physical summary items are summed and weighed Min value:0 Max value:100 Higher score indicates higher level of health | 30 days prior to Baseline | |
Secondary | SF-12 Health Survey Physical Summary Score at 1 Month | Physical summary items are summed and weighed Min value:0 Max value:100 Higher score indicates higher level of health | 1 month | |
Secondary | SF-12 Health Survey Physical Summary Score at 3 Months | Physical summary items are summed and weighed Min value:0 Max value:100 Higher score indicates higher level of health | 3 months | |
Secondary | SF-12 Health Survey Physical Summary Score at 6 Months | Physical summary items are summed and weighed Min value:0 Max value:100 Higher score indicates higher level of health | 6 months | |
Secondary | SF-12 Health Survey Mental Summary Score at Baseline | Mental summary items are summed and weighed Min value:0 Max value:100 Higher score indicates higher level of health | 30 days prior to Baseline | |
Secondary | SF-12 Health Survey Mental Summary Score at 1 Month | Mental summary items are summed and weighed Min value:0 Max value:100 Higher score indicates higher level of health | 1 month | |
Secondary | SF-12 Health Survey Mental Summary Score at 3 Months | Mental summary items are summed and weighed Min value:0 Max value:100 Higher score indicates higher level of health | 3 months | |
Secondary | SF-12 Health Survey Mental Summary Score at 6 Months | Mental summary items are summed and weighed Min value:0 Max value:100 Higher score indicates higher level of health | 6 months | |
Secondary | Treatment Motivation Questionnaire (TMQ) at Baseline | The TMQ will be used to measure self-reported interest in attending treatment Scores within each subscale are averaged
External: Min value:1 Max value:7 External:Higher score indicates higher external reasons for attending treatment (e.g.referred to treatment by legal system) Internal: Min value:1 Max value:7 Internal: Higher score indicates higher internal reasons for attending treatment (e.g. personal choice to attend treatment) |
30 days prior to Baseline | |
Secondary | Treatment Motivation Questionnaire (TMQ) at 1-month | The TMQ will be used to measure self-reported interest in attending treatment Scores within each subscale are averaged
External: Min value:1 Max value:7 External:Higher score indicates higher external reasons for attending treatment (e.g.referred to treatment by legal system) Internal: Min value:1 Max value:7 Internal: Higher score indicates higher internal reasons for attending treatment (e.g. personal choice to attend treatment) |
30 days prior to 1-month follow-up | |
Secondary | Treatment Motivation Questionnaire (TMQ) at 3-month | The TMQ will be used to measure self-reported interest in attending treatment Scores within each subscale are averaged
External: Min value:1 Max value:7 External:Higher score indicates higher external reasons for attending treatment (e.g.referred to treatment by legal system) Internal: Min value:1 Max value:7 Internal: Higher score indicates higher internal reasons for attending treatment (e.g. personal choice to attend treatment) |
60 days prior to 3-month follow-up | |
Secondary | Treatment Motivation Questionnaire (TMQ) at 6-months | The TMQ will be used to measure self-reported interest in attending treatment Scores within each subscale are averaged
External: Min value:1 Max value:7 External:Higher score indicates higher external reasons for attending treatment (e.g.referred to treatment by legal system) Internal: Min value:1 Max value:7 Internal: Higher score indicates higher internal reasons for attending treatment (e.g. personal choice to attend treatment) |
90 days prior to 6-month follow-up | |
Secondary | Fagerstrom Test for Nicotine Dependence at Baseline | Min:0 Max:10 Higher score indicates higher level of nicotine dependence | 30 days prior to Baseline | |
Secondary | Psychiatric Outpatient Satisfaction Scale - Total Score | Min:13 Max:65 Higher score indicates better satisfaction | 1 month | |
Secondary | Helping Alliance Questionnaire - Total Score | Participant completed assessment on the final day of group and rated therapist based on their interactions over the 4 days.
Min:19 Max:114 Higher score indicates stronger alliance with therapist |
Completed during session 4 of treatment group (i.e. the final treatment session) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05054738 -
CRP and S&A for Inpatient Veterans
|
N/A | |
Recruiting |
NCT04157062 -
An Open-Label Trial of Repetitive Transcranial Magnetic Stimulation for Opioid Use Disorder
|
N/A | |
Enrolling by invitation |
NCT06084221 -
Fatal Overdose Review Teams - Research to Enhance Surveillance Systems
|
N/A | |
Completed |
NCT02907944 -
Working With HIV Clinics to Adopt Addiction Treatments Using Implementation Facilitation
|
N/A | |
Completed |
NCT02570360 -
Exercise and Treatment-as-usual in Substance Use Treatment Outcomes
|
N/A | |
Completed |
NCT02829970 -
Helping College Students With ADHD Lead Healthier Lifestyles
|
N/A | |
Completed |
NCT02715557 -
Arise: An Online Relapse Prevention Tool for Adolescent Substance Abusers
|
N/A | |
Completed |
NCT02388243 -
The Computer-based Drug and Alcohol Training Assessment in Kenya
|
N/A | |
Completed |
NCT02125539 -
Field Trial of a Relapse Prevention Program for Adolescents Receiving Substance Use Treatment
|
Phase 2 | |
Completed |
NCT02945371 -
Tailored Inhibitory Control Training to Reverse EA-linked Deficits in Mid-life
|
N/A | |
Completed |
NCT01633138 -
Performance-based Reinforcement to Enhance Cognitive Remediation Therapy
|
N/A | |
Completed |
NCT02218970 -
The Effect of Muscular Strength Training in Patients With Drug Addiction
|
N/A | |
Completed |
NCT01591239 -
Home-Based Program to Help Parents of Drug Abusing Adolescents
|
N/A | |
Active, not recruiting |
NCT01539525 -
Screening to Augment Referral to Treatment- Project START
|
Phase 2 | |
Withdrawn |
NCT01224002 -
A Comparative Feasibility Study to Assess the Prevalence and Severity of Dental Caries in Incarcerated People Who Abuse Methamphetamine
|
N/A | |
Withdrawn |
NCT00891631 -
Primary Care iSBIRT to Reduce Serious Teen Health Risks
|
Phase 1/Phase 2 | |
Completed |
NCT00970372 -
Dual-Diagnosis and Compulsory Treatment
|
N/A | |
Completed |
NCT01365247 -
Concurrent Treatment for Substance Dependent Individuals With Post-Traumatic Stress Disorder (PTSD)
|
N/A | |
Completed |
NCT00419029 -
Motivational Interviewing to Engage Operations Enduring Freedom and Iraqi Freedom (OEF/OIF) Veterans in Mental Health Treatment
|
N/A | |
Completed |
NCT00247572 -
Safety, Tolerability and Abuse Liability Study of Intravenous NRP104 in Adults With Stimulant Abuse Histories
|
Phase 2 |